|
|
|
Digital X-Ray
Platform |
| |
CompuMed Announces
Kodak China Installs First OsteoGram®-Enhanced Digital X-Ray
Platform
Other Topics: Telemedicine
Equipment, Intelligent
Health Services, Clinical
Content Development
CompuMed, Inc.
November 27, 2006
Fully Integrated OsteoGram Functions Seamlessly to Provide
Cost-Effective Osteoporosis Testing
Los Angelis -- CompuMed, Inc. (OTCBB:CMPD) – a medical
informatics company leading the development of advanced imaging
technology for cost-effective analysis and monitoring –
announced today that the first OsteoGram-enhanced KODAK
DIRECTVIEW DR 3000 platform has been installed in Wuxi, China. |
| |
|
|
| |
CompuMed’s
OsteoGram is a software-based system for the screening,
diagnosing and monitoring of osteoporosis. The OsteoGram
provides an accurate, low-cost alternative to DXA bone mineral
density (BMD) testing. Earlier this year, CompuMed announced a
licensing agreement that enables Kodak Electronic Products
Shanghai Co., LTD (KEPS) to enhance its market-leading digital
radiography (DR) and computed radiography (CR) systems with
CompuMed's proprietary OsteoGram software. KEPS is a wholly
owned subsidiary of the Eastman Kodak Company (NYSE:EK).
“We are pleased to complete the project to integrate our
OsteoGram software with Kodak’s DR 3000 platform,” said CompuMed
CEO Jerry McLaughlin. “Now we can begin marketing the
first-of-its-kind integrated system to penetrate the world’s
largest osteoporosis market.”
According to China's 2000 national census, approximately 100
million of its citizens suffer from various stages of
osteoporosis, making China the nation with the world's highest
number of osteoporosis patients. The annual medical cost to
treat those affected by the disease is estimated to be about 15
billion Yuan ($84 billion US), a figure that does not take into
account the significant strain osteoporosis incurs on China's
national healthcare program.
CompuMed is planning to leverage its expertise in computer-aided
diagnostics to provide solutions and services that improve
healthcare provider workflow and patient care, while reducing
costs. The OsteoGram’s benefits in terms of cost and efficiency
facilitate wider osteoporosis screening and treatment for
at-risk patients. It is far less costly and cumbersome to use
than conventional BMD testing systems, which require dedicated
and expensive equipment, computers, office space and staff.
About CompuMed:
Founded in 1973, CompuMed, Inc. (OTCBB:CMPD) is leading the
development of advanced imaging and medical informatics
solutions that provide cost-effective analysis and monitoring.
CompuMed focuses on cardiovascular and musculoskeletal diseases,
as well as other diseases associated with aging populations. Its
unique expertise in telemonitoring, imaging and analysis
facilitates the development of new solutions and services
designed to improve healthcare provider workflow and patient
care, while reducing costs. CompuMed's core products, the
OsteoGram® and CardioGramTM systems, are cleared by the FDA and
reimbursable by Medicare. The OsteoGram is an accurate and
precise technology for osteoporosis testing. The underlying
OsteoGram technology has significant cost advantages over other
technologies and will be applied to a suite of value-added
applications, such as following the progression of arthritic
disease and diagnosing vertebral fractures and scoliosis. The
CardioGram system is one of the first telecommunication networks
designed to remotely interpret electrocardiograms and is used by
private practice, as well as government and corporate healthcare
providers nationwide. The CardioGram delivers online
electrocardiogram interpretations within two minutes of receipt,
and has the additional capability to automatically provide an
over-read (i.e., follow- up review) by a cardiologist. CompuMed
is headquartered in Los Angeles. Visit CompuMed at
www.compumed.net.
This news release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks, including, but not limited to, product
and service demand and acceptance, changes in technology,
ability to raise capital, availability of appropriate
acquisition candidates and/or business partnerships, economic
conditions, impact of competition and pricing, capacity and
supply constraints or difficulties, government regulation and
other risks defined in this document. All such forward-looking
statements whether written or oral, and whether made by or on
behalf of the Companies are expressly qualified by these
cautionary statements and any other cautionary statements which
may accompany the forward-looking statements. In addition, the
Company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. |
| |
|
|
| |
|
|
